492 related articles for article (PubMed ID: 11545541)
21. Single-agent capecitabine in patients with metastatic colorectal cancer refractory to 5-fluorouracil/leucovorin chemotherapy.
Lee JJ; Kim TM; Yu SJ; Kim DW; Joh YH; Oh DY; Kwon JH; Kim TY; Heo DS; Bang YJ; Kim NK
Jpn J Clin Oncol; 2004 Jul; 34(7):400-4. PubMed ID: 15342667
[TBL] [Abstract][Full Text] [Related]
22. Role of oral chemotherapy in colorectal cancer.
Donehower RC
Oncology (Williston Park); 2000 Nov; 14(11A):243-5. PubMed ID: 11195416
[TBL] [Abstract][Full Text] [Related]
23. Which endpoints should we use in evaluating the use of novel fluoropyrimidine regimens in colorectal cancer?
Twelves CJ; Cassidy J
Br J Cancer; 2002 Jun; 86(11):1670-6. PubMed ID: 12087448
[TBL] [Abstract][Full Text] [Related]
24. Capecitabine plus oxaliplatin for the treatment of colorectal cancer.
Carrato A; Gallego-Plazas J; Guillén-Ponce C
Expert Rev Anticancer Ther; 2008 Feb; 8(2):161-74. PubMed ID: 18279056
[TBL] [Abstract][Full Text] [Related]
25. The role of UFT in metastatic colorectal cancer.
Bennouna J; Saunders M; Douillard JY
Oncology; 2009; 76(5):301-10. PubMed ID: 19299903
[TBL] [Abstract][Full Text] [Related]
26. [Capecitabine].
Yamaguchi K; Shimamura T; Tada M
Gan To Kagaku Ryoho; 2006 Jul; 33(7):891-5. PubMed ID: 16835474
[TBL] [Abstract][Full Text] [Related]
27. The role of capecitabine in the treatment of colorectal cancer in the elderly.
Pasetto LM; Monfardini S
Anticancer Res; 2006; 26(3B):2381-6. PubMed ID: 16821620
[TBL] [Abstract][Full Text] [Related]
28. UFT in the treatment of colorectal and breast cancer.
Sun W; Haller D
Oncology (Williston Park); 2001 Jan; 15(1 Suppl 2):49-56. PubMed ID: 11219978
[TBL] [Abstract][Full Text] [Related]
29. Treatment of colorectal cancer metastasis: the role of chemotherapy.
Xiong HQ; Ajani JA
Cancer Metastasis Rev; 2004; 23(1-2):145-63. PubMed ID: 15000155
[TBL] [Abstract][Full Text] [Related]
30. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
Van Cutsem E; Twelves C; Cassidy J; Allman D; Bajetta E; Boyer M; Bugat R; Findlay M; Frings S; Jahn M; McKendrick J; Osterwalder B; Perez-Manga G; Rosso R; Rougier P; Schmiegel WH; Seitz JF; Thompson P; Vieitez JM; Weitzel C; Harper P;
J Clin Oncol; 2001 Nov; 19(21):4097-106. PubMed ID: 11689577
[TBL] [Abstract][Full Text] [Related]
31. A cost comparison of oral tegafur plus uracil/folinic acid and parenteral fluorouracil for colorectal cancer in Canada.
Maroun J; Asche C; Romeyer F; Mukherjee J; Cripps C; Oza A; Skillings J; Letarte J
Pharmacoeconomics; 2003; 21(14):1039-51. PubMed ID: 13129416
[TBL] [Abstract][Full Text] [Related]
32. Oral capecitabine: bridging the Atlantic divide in colon cancer treatment.
Van Cutsem E; Verslype C; Tejpar S
Semin Oncol; 2005 Feb; 32(1):43-51. PubMed ID: 15726505
[TBL] [Abstract][Full Text] [Related]
33. Oral fluoropyrimidines in the treatment of colorectal cancer.
Meropol NJ
Eur J Cancer; 1998 Sep; 34(10):1509-13. PubMed ID: 9893621
[TBL] [Abstract][Full Text] [Related]
34. [Systemic treatment of colorectal cancers--factual standards and perspectives].
Miron L
Rev Med Chir Soc Med Nat Iasi; 2003; 107(4):752-8. PubMed ID: 14756014
[TBL] [Abstract][Full Text] [Related]
35. Oral uracil-tegafur plus leucovorin vs fluorouracil bolus plus leucovorin for advanced colorectal cancer: a meta-analysis of five randomized controlled trials.
Bin Q; Li J; Liao C; Cao Y; Gao F
Colorectal Dis; 2011 Aug; 13(8):837-45. PubMed ID: 20050863
[TBL] [Abstract][Full Text] [Related]
36. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer.
Cassidy J; Tabernero J; Twelves C; Brunet R; Butts C; Conroy T; Debraud F; Figer A; Grossmann J; Sawada N; Schöffski P; Sobrero A; Van Cutsem E; Díaz-Rubio E
J Clin Oncol; 2004 Jun; 22(11):2084-91. PubMed ID: 15169795
[TBL] [Abstract][Full Text] [Related]
37. Capecitabine chemotherapy for metastatic colorectal cancer. Chemical structure, combinations and efficacy.
Koukourakis G; Kouloulias V; Zacharias G; Koukourakis M
J BUON; 2010; 15(4):652-9. PubMed ID: 21229625
[TBL] [Abstract][Full Text] [Related]
38. Is XELOX equivalent to FOLFOX or other continuous-infusion 5-fluorouracil chemotherapy in metastatic colorectal cancer?
Douillard JY; Bennouna J; Senellart H
Clin Colorectal Cancer; 2008 May; 7(3):206-11. PubMed ID: 18621641
[TBL] [Abstract][Full Text] [Related]
39. Fluoropyrimidines: a critical evaluation.
Brito RA; Medgyesy D; Zukowski TH; Royce ME; Ravandi-Kashani F; Hoff PM; Pazdur R
Oncology; 1999 Jul; 57 Suppl 1():2-8. PubMed ID: 10436410
[TBL] [Abstract][Full Text] [Related]
40. Patient preference for oral or intravenous chemotherapy: a randomised cross-over trial comparing capecitabine and Nordic fluorouracil/leucovorin in patients with colorectal cancer.
Pfeiffer P; Mortensen JP; Bjerregaard B; Eckhoff L; Schønnemann K; Sandberg E; Aabo K; Jakobsen A
Eur J Cancer; 2006 Nov; 42(16):2738-43. PubMed ID: 17011184
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
